Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

Immix Biopharma, Inc.

Immix Biopharma, Inc. (ImmixBio™) is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases. Our lead asset, IMX-110, is currently in phase 1b/2a clinical trials for solid tumors in the United States and Australia. Our proprietary System Multi-Action RegulaTors SMARxT Tissue-Specific Platform produces drugs that accumulate at intended therapeutic sites at 3-5 times that of conventional medicines. Our TME Normalization™ Technology allows our drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the tumor micro-environment, or TME. We have uncovered fundamental biological systems that link oncology and inflammation. Our pipeline includes pre-clinical tissue-specific therapeutics to treat inflammatory bowel disease, including ulcerative colitis and Crohn’s disease.

Mesa Verde Venture Partners

Immix Biopharma (Nasdaq: IMMX)

Immix Biopharma Announces Complete Response in 9th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial at IMS 20th Annual Meeting

Read the press release here: https://loom.ly/1Pu09G0

#cancertreatment #biopharma #sciencenews

Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma

Read the press release here: https://loom.ly/4PQGN9c

#science #biopharma #cancertreatment #multiplemyeloma #car-t

Immix Biopharma Subsidiary Nexcella Completes 2nd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site

Read the press release here: https://loom.ly/HCKoAzU

#cancertreatment #science #biopharma

Immix Biopharma is pioneering a novel class of Tissue-Specific Therapeutics (TSTx)™ 

Read more here: https://lnkd.in/emdDgvbQ

#science #cancertreatment #technology

Immix Biopharma's subsidiary Nexcella, Inc. 

Learn more about Nexcella, Inc.: https://nexcella.com/  

#biopharma #cancertreatment #science

Who founded Immix Biopharma?

Read more here: https://lnkd.in/enZ6FH3s 

#science #cancer #biopharma

Nexcella, Immix Biopharma Subsidiary, to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference

#healthcare #science #biopharma

Dr. Suzanne Lentzsch Joins Immix Biopharma Scientific Advisory Board

Read the press release here: https://loom.ly/spWfYjU

#sciencenews #biopharma

FDA Orphan Drug Designation (“ODD”) qualifies NXC-201 for the following: 

Read the press release here: https://loom.ly/fwrLYNQ

#fda #science #cancer

U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Multiple Myeloma

Read the press release here: https://loom.ly/fwrLYNQ 

#science #biopharma #sciencenews

NASDAQ:IMMX

Immix Biopharma, Inc.

Last Close

2.15

26/07 20:00

Market Cap

53.89M

Beta: -

Volume Today

125.04K

Avg: 208.58K

PE Ratio

−4.23

PFCF: −5.01

Financials Not Available